Cosmos Health Inc. — Form 8-K
Filed August 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cosmos Health (market cap ~$9.5M) reported Q2 2026 revenue of $19.0M (+28.8% YoY) and H1 revenue of $36.9M (+29.7% YoY), reaching an annualized run-rate exceeding $75M. The company reduced total liabilities by $6.27M (13.3%), increased stockholders' equity 12.2% to $20.67M, and authorized a $5M share repurchase program (5.1M shares repurchased for ~$1.11M as of filing date). However, GAAP net loss widened to ($6.09M) in Q2 due to $2.65M in non-cash fair-value adjustments on financing arrangements, while adjusted EBITDA remained negative at ($1.13M).
Why this rating
Strong revenue growth (29.8%) relative to tiny $9.5M market cap is material; however, persistent GAAP losses and negative adjusted EBITDA offset optimism. Share buyback signals management confidence but consumes scarce cash.
See more from August 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.